Tsumura & Co
TSE:4540
Tsumura & Co
Long-Term Debt
Tsumura & Co
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Tsumura & Co
TSE:4540
|
Long-Term Debt
¥65.1B
|
CAGR 3-Years
18%
|
CAGR 5-Years
11%
|
CAGR 10-Years
16%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Long-Term Debt
¥4.7T
|
CAGR 3-Years
4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
19%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Long-Term Debt
¥100.9B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-7%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Long-Term Debt
¥160.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
22%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Long-Term Debt
¥4.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
38%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Long-Term Debt
¥564.9B
|
CAGR 3-Years
117%
|
CAGR 5-Years
34%
|
CAGR 10-Years
97%
|
|
Tsumura & Co
Glance View
Tsumura & Co., a venerable name in the herbal medicine industry, traces its roots back to 1893. Emerging from Japan's rich pharmacopeia tradition, the company has carved a niche by blending age-old herbal knowledge with contemporary research and quality control. This synergy allows Tsumura to thrive in the modern marketplace, offering Kampo—a traditional Japanese herbal medicine—as their primary product line. Tsumura stands out in its meticulous approach to sourcing high-quality raw materials, employing state-of-the-art technology to ensure efficacy and safety. This rigorous quality assurance not only honors the integrity of traditional formulas but also aligns with the stringent standards of modern healthcare. In its pursuit of growth, Tsumura expertly navigates the delicate balance between tradition and innovation. The company generates revenue through the sale of its Kampo products, which are widely used in clinics and hospitals across Japan, reflecting a significant integration into the mainstream healthcare system. Additionally, Tsumura's strategic collaborations with pharmaceutical companies expand its reach into international markets. Through educational initiatives, they further advocate for the understanding and acceptance of herbal medicine globally. By continually investing in research and development, Tsumura aims to bolster their product offerings, ensuring that the ancient wisdom of Kampo remains relevant in today's fast-paced, health-conscious world.
See Also
What is Tsumura & Co's Long-Term Debt?
Long-Term Debt
65.1B
JPY
Based on the financial report for Dec 31, 2024, Tsumura & Co's Long-Term Debt amounts to 65.1B JPY.
What is Tsumura & Co's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
16%
Over the last year, the Long-Term Debt growth was 20%. The average annual Long-Term Debt growth rates for Tsumura & Co have been 18% over the past three years , 11% over the past five years , and 16% over the past ten years .
You don't have any saved screeners yet